BioAtla, Inc. (BCAB): Shareholders' Equity
$36.19M
As of 2025-12-31
-$36.24M
As of 2026-06-30
-41.5%
3-year compound annual growth
-29.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $36.19M | +153.7% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $14.27M | -79.8% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $70.67M | -60.8% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $180.34M | -14.5% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $210.82M | +0.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $209.97M | n/m | 2022-02-28, Balance as of period end |
| 2019-12-31 | -$56.01M | n/a | 2022-02-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | 2025-12-31 | $36.19M | +153.7% |
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $11.88M | +307.0% |
| MiNK Therapeutics, Inc. (INKT) | 2025-12-31 | -$14.23M | n/m |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $13.10M | +62.1% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $8.10M | -18.8% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$32.19M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | $1.23M | -50.1% |
| Greenland Mines Ltd (GRML) | 2025-12-31 | $9.46M | +698.4% |
| Curis Inc (CRIS) | 2025-12-31 | $5.46M | n/m |
Compare BCAB, INTS, INKT, ENTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗